InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.17
(
-0.25%
)
US TECH 100
19,214.80
(
-0.23%
)
Dow Jones
39,134.76
(
0.77%
)
Brent Oil
84.87
(
-0.16%
)
Bitcoin
63,795.18
(
-1.58%
)
Post# of 608
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

mlkrborn

Send PM Follow Ignore
Followers 40
Posts 7682
Boards Moderated 1
Alias Born 01/04/2006

mlkrborn

Re: mlkrborn post# 151

Friday, 04/05/2013 2:56:25 PM

Friday, April 05, 2013 2:56:25 PM

Post# of 608
RIGL -29.6% (AstraZeneca reports top-line results from OSKIRA-1 Phase 3 study of Fostamatinib in Rheumatoid Arthritis, Rigel Pharma downgraded to Market Perform from Outperform at BMO Capital Mkts),
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent RIGL News
More RIGL News
InvestorsHub NewsWire

Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM

ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM

North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM

VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM

Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM

Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM

Start posting your company's news
Only $200 per official company press release!